FUSIONSPOLYPEPTID GEGEN KREBS

European patent · EP3298030 · In force

Register entry

Publication number
EP3298030
Application number
EP16729794
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 18, 2016
Published
Mar 28, 2018
Granted
Jan 18, 2023
Protection ends at the latest
May 17, 2036
Next annual fee due
May 31, 2026
IPC classes
C07K 14/47 (2006.01)
C07K 16/28 (2006.01)
C07K 14/705 (2006.01)
Priority
EP 15167927 18.05.2015
EP 16150508 08.01.2016
PCT application
PCT/EP2016/061071 18.05.2016
PCT publication
WO2016/184882 24.11.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  2. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  3. Nov 29, 2023

    Change

    Published in Swissreg on 29.11.2023

  4. Jun 1, 2023

    Change

    Published in Swissreg on 01.06.2023

  5. Jan 19, 2023

    Agent entered

    Representative
    BOVARD AG, Patent- und Markenanwälte, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 19.01.2023

  6. Jan 18, 2023

    Granted

    Published in Swissreg on 18.01.2023

Parties

Holder

Pieris Pharmaceuticals GmbH

Lise-Meitner-Strasse 30, 85354 Freising-Weihenstephan, DE

Agent

Bovard AG

BOVARD AG

Patent- und Markenanwälte Optingenstrasse 16, 3013 Bern

Inventor

ROTHE, Christine

85221 Dachau, DE

HINNER, Marlon

81247 Munich, DE

BEL AIBA, Rachida, Siham

80469 Munich, DE

SCHLOSSER, Corinna

85354 Freising, DE

OLWILL, Shane

85354 Freising, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.